Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICLE 2022 | Highlights from ICLE 2022

Tuna Mutis • 1 Apr 2022
ICLE 2022
General CAR-T

Tuna Mutis, MD, PhD, Amsterdam University Medical Center, Amsterdam, The Netherlands, provides his highlights from the International Conference on Lymphocyte Engineering (ICLE) 2022, including presentations on the latest in T-cell receptor engineering as well as novel developments in the field of HLA-independent T-cell (HIT) receptors that will aim to optimize current chimeric antigen receptor (CAR) T-cell therapies. This interview took place at ICLE 2022.

More from Tuna Mutis

Focusing on allogeneic CAR T-cell therapies for myeloma
0:57
Focusing on allogeneic CAR T-cell therapies for myeloma
Tuna Mutis • 1 Apr 2022
Current research on anti-CD38 CAR T-cell therapies
1:09
Current research on anti-CD38 CAR T-cell therapies
Tuna Mutis • 1 Apr 2022
Relapsing from CAR T-cells in multiple myeloma
2:15
Relapsing from CAR T-cells in multiple myeloma
Tuna Mutis • 1 Apr 2022
The future of immunotherapy in multiple myeloma
11:24
The future of immunotherapy in multiple myeloma
Hearn Jay Cho et al. • 18 Oct 2017

Related Videos

The ethical challenges of AI in hematology: patient communication, trust and regulation
3:12
The ethical challenges of AI in hematology: patient communication, trust and regulation
Adrián Mosquera Orgueira • 24 Sep 2026
The future of AI in hematology: personalized medicine, opportunities and risks
2:30
The future of AI in hematology: personalized medicine, opportunities and risks
Adrián Mosquera Orgueira • 24 Sep 2026
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
5:18
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
Shyam Patel • 13 Oct 2026
The scientific and clinical implications of therapy-related CHIP in oncology
2:43
The scientific and clinical implications of therapy-related CHIP in oncology
Shyam Patel • 13 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals